This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Recognize warning signs your budget is bad and learn practical tweaks to restore balance and reliability.
19,039 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
A sudden explosion at Valero’s Port Arthur refinery prompted a temporary shutdown, sending ripples through energy mar...
Apyx Medical (APYX) 2026 is shaping up as a pivotal year for investors. This guide breaks down how to read the Q1 tra...
Alibaba's latest earnings mix puts cloud momentum in the spotlight while profitability falters. This article untangle...
Boxer Capital quietly boosted its stake in Corvus Pharmaceuticals, a move that signals institutional faith in the bio...
A disciplined, calendar-driven approach to investing is gaining ground as markets swing on tariff news and rate moves...
A hypothetical partnership could redirect USDC yield to buybacks, potentially lifting Hyperliquid's value. This guide...
Nvidia sits at a pivotal crossroads as driverless technology could next reshape how auto tech and AI collide. This ar...
A veteran financial writer dives into a framework that aims to outpace the S&P over generations. Learn how Davis Fund...
Regulators warn of a loophole that allows new chemicals to enter foods and supplements without premarket approval. Th...
As markets shift in 2026, experts weigh dave ramsey’s social security guidance against standard planning rules, highl...
Savers face a rate tug-of-war in 2026 as money market accounts high yields compete with high yield savings accounts. ...